2022
Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Loo Gan C, Huang J, Pan E, Xie W, Schmidt A, Labaki C, Meza L, Bouchard G, Li H, Jackson-Spence F, Sánchez-Ruiz C, Powles T, Kumar S, Weise N, Hall W, Rose B, Beuselinck B, Suarez C, Pal S, Choueiri T, Heng D, McKay R. Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology Oncology 2022, 6: 204-211. PMID: 36328934, DOI: 10.1016/j.euo.2022.10.004.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaMRCC treated with cabozantinibRenal cell carcinomaAdverse eventsRisk-benefit assessmentCell carcinomaReceiving radiotherapyInternational Metastatic Renal Cell Carcinoma Database ConsortiumPatients treated with stereotactic ablative body radiotherapyInternational multicenter retrospective studyStereotactic ablative body radiotherapyPractice patternsConventional palliative radiotherapyGrade 5 eventsIntermediate-risk diseaseReceipt of radiotherapyMultiple brain metastasesMetastatic kidney cancerRadiotherapy-related toxicityCourse of radiotherapyEfficacy of cabozantinibMulticenter retrospective studyStudy of patientsOptimize treatment outcomesAssessment of patients
2021
Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma
Meza L, Malhotra J, Favorito C, Pal S. Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma. Future Oncology 2021, 18: 21-33. PMID: 34766841, DOI: 10.2217/fon-2021-0570.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMetastatic renal cell carcinomaMetastatic urothelial carcinomaTargeted therapyTreatment of metastatic RCCMetastatic renal cellNonresponders to monotherapyRenal cell carcinomaIncrease clinical responsesImmunotherapy combinationsMetastatic RCCUrothelial carcinomaClinical responseCell carcinomaProgressive diseaseIO agentsTreatment optionsRenal cellsImmunotherapyQuality of lifeCabozantinibMonotherapyCarcinomaNovel approachesNonrespondersTherapy